Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Journal: Journal of comparative effectiveness research
Published: August 21, 2026
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.
Journal: Future oncology (London, England)
Published: July 30, 2026
Physician and Patient Perception of Disease, Symptomatology, and Treatment Administration Preference in Paroxysmal Nocturnal Haemoglobinuria: Results from a Real-World Survey.
Journal: Advances in therapy
Published: April 14, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.
Journal: Advances in therapy
Published: April 01, 2026
Multifunctional treatment of emerging estrogenic micropollutants: a review of biological, chemical, and physicochemical pathways.
Journal: Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering
Published: March 13, 2026
Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.
Journal: British journal of haematology
Published: February 28, 2026
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
Journal: American journal of hematology
Published: February 05, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.
Journal: British journal of haematology
Published: December 08, 2025
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.
Journal: The New England journal of medicine
Published: December 03, 2025
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.
Journal: Future oncology (London, England)
Published: November 01, 2025
Last Updated: 09/26/2026